Drug intelligence / Profile preview

P-21

Development stage: Preclinical
Lead developer: Shifa Biomedical
Modality: Small Molecules

Overview

P-21 is an experimental small-molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor that has been developed by Shifa Biomedical as a lipid-lowering agent targeting dyslipidemia and related cardiovascular risk by enhancing LDL receptor recycling and lowering LDL cholesterol. As a PCSK9 inhibitor, P-21 is designed to block PCSK9-mediated degradation of hepatic LDL receptors, thereby increasing clearance of circulating LDL particles. Public information indicates that P-21 remains in early development with no active clinical indications disclosed.

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on P-21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-21.

Explore the full profile